BVAC-E6E7 (low level)
Preclinical
BVAC-E6E7 (low level) is one of 10 therapeutic programs targeting Head and Neck Squamous Cell Carcinoma (HNSCC). It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
13 competitors in Head and Neck Squamous Cell Carcinoma (HNSCC)
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 2
Opdualag
Bristol-Myers SquibbPhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Libtayo
RegeneronPhase 2
Erbitux
IImclone
Phase 1
FDC Fianlimab+cemiplimab
RegeneronPhase 2
Ezabenlimab
Boehringer IngelheimPhase 1
Pembolizumab
SShanghai JMT-Bio Inc.
Preclinical
Axelopran
HHealthPartners Institute
Preclinical
BVAC-E6E7 (low level)
CCellid Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for BVAC-E6E7 (low level). EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company
- CCellid Co., Ltd.